Evidence map›Paper›PMID 27966448›Full record

ArticleOncotarget2017

Differential expression of peroxiredoxin 3 in laryngeal squamous cell carcinoma.

Hua Zhang, Xuexia Liu, Lei Chen, Li Cai, Ning Li, Peng Zhu, Jian Chen, Xicheng Song, Guojun Li

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Hua ZhangDepartment of Otolaryngology-Head and Neck Surgery, Yuhuangding Hospital of Qingdao University, Yantai, China.
Xuexia LiuDepartment of Central Laboratory, Yuhuangding Hospital of Qingdao University, Yantai, China.
Lei ChenDepartment of Clinical Laboratory, Yuhuangding Hospital of Qingdao University, Yantai, China.
Li CaiDepartment of Pathology, Yuhuangding Hospital of Qingdao University, Yantai, China.
Ning LiDepartment of Central Laboratory, Yuhuangding Hospital of Qingdao University, Yantai, China.
Peng ZhuDepartment of Central Laboratory, Yuhuangding Hospital of Qingdao University, Yantai, China.
Jian ChenDepartment of Central Laboratory, Yuhuangding Hospital of Qingdao University, Yantai, China.
Xicheng SongDepartment of Otolaryngology-Head and Neck Surgery, Yuhuangding Hospital of Qingdao University, Yantai, China.
Guojun LiDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Qingdao University · CNYuhuangding Hospital · CNThe University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peroxiredoxin (PRDX) proteins are involved in carcinogenesis. PRDX3, which is predominantly localized in mitochondria and up-regulated in several human cancers, seems to confer increased treatment resistance and aggressive phenotypes. This study examined the expression profile of PRDX3 and its possible clinical value in laryngeal squamous cell carcinoma (LSCC). The expression of PRDX3 in LSCC samples was confirmed by Western blotting and further analyzed by immunohistochemistry in LSCC samples of different clinical pathological stages. The results showed that up-regulated expression of PRDX3 was observed in LSCC and associated with poor differentiation (P < 0.01), primary tumor location, N category and tumor stage (P < 0.05). Knockdown of PRDX3 in the Hep-2 laryngeal carcinoma epithelial cell line significantly enhanced Hep-2 cells' apoptosis and inhibited their proliferation and migration. Taken together, our results suggest that PRDX3 has substantial clinical impact on the progression of LSCC and shed new light on the role of PRDX3 in treatment resistance and aggressive phenotypes in LSCC.

Indexed as

Gene Expression Regulation, NeoplasticAdultAgedAged, 80 and overCarcinoma, Squamous CellCell Line, TumorCell MovementCell ProliferationCombined Modality TherapyFemaleHumansKaplan-Meier EstimateLaryngeal NeoplasmsMaleMiddle AgedNeoplasm GradingPeroxiredoxin IIIPRDX3 protein, humanHep-2 cell linelaryngeal squamous cell carcinomaoxidative stressperoxiredoxin 3

Identifiers

PMID27966448
PMCPMC5356896
OpenAlexW2560827698

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.